A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer

被引：7

作者：

Puglisi, Fabio ^{[1
]}

Bisagni, Giancarlo ^{[2
]}

Ciccarese, Mariangela ^{[3
]}

Fontanella, Caterina ^{[1
]}

Gamucci, Teresa ^{[4
]}

Leo, Luigi ^{[5
]}

Molino, Annamaria ^{[6
]}

Silva, Rosa Rita ^{[7
]}

Marchetti, Paolo ^{[8
,9
]}

机构：

[1] Univ Udine, Dept Med & Biol Sci, Udine, Italy

[2] Azienda Osped ASMN, Dept Oncol, Oncol Unit, Ist Ricovero & Cura Carattere Sci, Reggio Emilia, Italy

[3] Vito Fazzi Hosp, Dept Med Oncol, Lecce, Italy

[4] ASL Frosinone, Med Oncol Unit, Frosinone, Italy

[5] Azienda Osped Colli, Oncol Unit, Naples, Italy

[6] Univ Verona, Verona, Italy

[7] ASUR Marche AV2 Fabriano, Med Oncol Unit, Fabriano, Italy

[8] Sapienza Univ Rome, Med Oncol, St Andrea Hosp, Rome, Italy

[9] IDI IRCCS, Rome, Italy

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 22期

关键词：

angiogenesis; bevacizumab; breast cancer; PROGRESSION-FREE SURVIVAL; PHASE-III TRIAL; CONTAINING THERAPY; OPEN-LABEL; NEOADJUVANT CHEMOTHERAPY; PLUS BEVACIZUMAB; TARGETED THERAPIES; AND/OR BEVACIZUMAB; LOCALLY RECURRENT; CLINICAL-PRACTICE;

D O I：

10.2217/fon-2016-0295

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.

引用

页码：2589 / 2602

页数：14

共 77 条

[1] Analysis of PD-L1 and RAD50 in circulating cells recovered from lung cancer patients before and after induction of radiotherapy. [J].

Adams, Daniel L. ;

Edelman, Martin J. ;

Alpaugh, R. Katherine ;

He, Jianzhong ;

Xu, Ting ;

Gao, Hui ;

Reuben, James M. ;

Qiao, Yawei ;

Hahn, Stephen M. ;

Komaki, Ritsuko ;

Liao, Zhongxing X. ;

Tang, Cha-Mei ;

Lin, Steven H. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[2] Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis [J].

Adunlin, George ;

Cyrus, John W. W. ;

Dranitsaris, George .

BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (03) :591-608

[3] Bevacizumab: the phoenix of breast oncology? [J].

Andre, Fabrice ;

Deluche, Elise ;

Bonnefoi, Herve .

LANCET ONCOLOGY, 2015, 16 (06) :600-601

[4] First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study [J].

Aogi, Kenjiro ;

Masuda, Norikazu ;

Ohno, Shinji ;

Oda, Takashi ;

Iwata, Hiroji ;

Kashiwaba, Masahiro ;

Fujiwara, Yasuhiro ;

Kamigaki, Shunji ;

Ito, Yoshinori ;

Ueno, Takayuki ;

Takashima, Shigemitsu .

BREAST CANCER RESEARCH AND TREATMENT, 2011, 129 (03) :829-838

[5] Features of aggressive breast cancer [J].

Arpino, Grazia ;

Milano, Monica ;

De Placido, Sabino .

BREAST, 2015, 24 (05) :594-600

[6] Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial [J].

Bear, Harry D. ;

Tang, Gong ;

Rastogi, Priya ;

Geyer, Charles E., Jr. ;

Liu, Qing ;

Robidoux, Andre ;

Baez-Diaz, Luis ;

Brufsky, Adam M. ;

Mehta, Rita S. ;

Fehrenbacher, Louis ;

Young, James A. ;

Senecal, Francis M. ;

Gaur, Rakesh ;

Margolese, Richard G. ;

Adams, Paul T. ;

Gross, Howard M. ;

Costantino, Joseph P. ;

Paik, Soonmyung ;

Swain, Sandra M. ;

Mamounas, Eleftherios P. ;

Wolmark, Norman .

LANCET ONCOLOGY, 2015, 16 (09) :1037-1048

[7] Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer [J].

Bear, Harry D. ;

Tang, Gong ;

Rastogi, Priya ;

Geyer, Charles E., Jr. ;

Robidoux, Andre ;

Atkins, James N. ;

Baez-Diaz, Luis ;

Brufsky, Adam M. ;

Mehta, Rita S. ;

Fehrenbacher, Louis ;

Young, James A. ;

Senecal, Francis M. ;

Gaur, Rakesh ;

Margolese, Richard G. ;

Adams, Paul T. ;

Gross, Howard M. ;

Costantino, Joseph P. ;

Swain, Sandra M. ;

Mamounas, Eleftherios P. ;

Wolmark, Norman .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04) :310-320

[8]

Bianchini G, 2016, NAT REV CLIN ONCOL, DOI [10.1038/nrclinonc.2016.66, DOI 10.1038/NRCHNONC.201.6.66]

[9] First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study [J].

Biganzoli, L. ;

Di Vincenzo, E. ;

Jiang, Z. ;

Lichinitser, M. ;

Shen, Z. ;

Delva, R. ;

Bogdanova, N. ;

Vivanco, G. L. ;

Chen, Z. ;

Cheng, Y. ;

Just, M. ;

Espie, M. ;

Vinholes, J. ;

Hamm, C. ;

Crivellari, D. ;

Chmielowska, E. ;

Semiglazov, V. ;

Dalenc, F. ;

Smith, I. .

ANNALS OF ONCOLOGY, 2012, 23 (01) :111-118

[10] Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines? [J].

Bonotto, Marta ;

Gerratana, Lorenzo ;

Iacono, Donatella ;

Minisini, Alessandro Marco ;

Rihawi, Karim ;

Fasola, Gianpiero ;

Puglisi, Fabio .

ONCOLOGIST, 2015, 20 (07) :719-724

← 1 2 3 4 5 6 7 8 →